[Discontinuation of psychotropic medication: a critical review of the evidence]
- PMID: 39749596
[Discontinuation of psychotropic medication: a critical review of the evidence]
Abstract
Background: Pharmacotherapy is an effective treatment strategy for psychiatric disorders. Nevertheless, many patients discontinue their medication at some point. Evidence-based practices for patients, clinicians, and policymakers to discontinue psychotropic medication properly are therefore important. However, guidelines and consensus papers on this topic have been limited in numbers and scope.
Aim: To provide a summary and critical review of the scientific evidence on discontinuation of four classes of psychotropic medication: antidepressants, antipsychotics, benzodiazepines and mood stabilizers.
Method: Experts on each medication class conducted a literature review and convened in consensus meetings to identify similarities and differences between the medication classes. For each class, the following questions are discussed: 1. who can discontinue (including risk of relapse, risk of withdrawal symptoms); 2. when to discontinue (including optimal duration of medication use); and 3. how to discontinue (including interventions to reduce the risk of relapse, dose reduction versus complete discontinuation). Similarities and differences between the classes are described.
Results: Abrupt or rapid discontinuation of most psychotropic medications results in more withdrawal symptoms compared to gradual tapering and a doubled risk of relapse compared to continued treatment. Additionally, several patient characteristics are associated with successful discontinuation of psychotropic medications. Furthermore, marked differences exist in the optimal timing and speed of tapering for each medication class.
Conclusion: Integrating and comparing scientific knowledge on discontinuation of different classes of psychotropic medications provides patients and professionals with guidance to make informed decisions about discontinuation and identifies knowledge gaps. There is a need for research on the role of pharmacotherapeutic tapering schedules and supportive psychological interventions, focusing on patient-relevant outcome measures (such as social functioning).
Similar articles
-
Discontinuation of psychotropic medication: a synthesis of evidence across medication classes.Mol Psychiatry. 2024 Aug;29(8):2575-2586. doi: 10.1038/s41380-024-02445-4. Epub 2024 Mar 19. Mol Psychiatry. 2024. PMID: 38503923 Free PMC article. Review.
-
Acute and Persistent Withdrawal Syndromes Following Discontinuation of Psychotropic Medications.Psychother Psychosom. 2020;89(5):283-306. doi: 10.1159/000506868. Epub 2020 Apr 7. Psychother Psychosom. 2020. PMID: 32259826 Review.
-
Approaches for discontinuation versus continuation of long-term antidepressant use for depressive and anxiety disorders in adults.Cochrane Database Syst Rev. 2021 Apr 15;4(4):CD013495. doi: 10.1002/14651858.CD013495.pub2. Cochrane Database Syst Rev. 2021. PMID: 33886130 Free PMC article.
-
Psychotropic medication use in people living with severe and persistent mental illness in the Australian community: a cross-sectional study.BMC Psychiatry. 2022 Nov 15;22(1):705. doi: 10.1186/s12888-022-04324-0. BMC Psychiatry. 2022. PMID: 36380352 Free PMC article.
-
Using antipsychotic agents in older patients.J Clin Psychiatry. 2004;65 Suppl 2:5-99; discussion 100-102; quiz 103-4. J Clin Psychiatry. 2004. PMID: 14994733 Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical